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Background: Approximately 35 million people world-wide have Alzheimer’s disease and this is projected to nearly
double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and
rivastigmine) and memantine (N-methyl-D-aspartic acid (NMDA) receptor antagonist) have been approved for the
treatment of Alzheimer’s disease in many countries. Our objective is to evaluate the comparative effectiveness,
safety, and cost of cognitive enhancers for Alzheimer’s disease through a systematic review.
Methods/design: Studies examining the efficacy, safety, and cost of cognitive enhancers compared to placebo,
supportive care, and other cognitive enhancers for Alzheimer’s patients will be included. The primary outcome is
cognition and secondary outcomes include function, behavior, quality of life, safety, and cost. Experimental studies
(randomized controlled trials, quasi-randomized controlled trials, controlled clinical trials), quasi-experimental studies
(controlled before-after, interrupted time series), and observational studies (cohort, case–control studies) will be eligible
for inclusion. Inclusion will not be limited by publication status, time period or language of dissemination.
We will search electronic databases (for example, MEDLINE, Cochrane Central Register of Controlled Trials, EMBASE,
CINAHL, Ageline) from inception onwards. The electronic database search will be supplemented by searching for grey
literature (for example, conference proceedings, searches in Google and relevant organization websites). Two reviewers
will independently screen the studies for inclusion using the eligibility criteria established a priori and independently
extract data. Risk of bias will be assessed using the Cochrane Risk of Bias tool for experimental and quasi-experimental
studies and the Newcastle Ottawa Scale for observational studies. If deemed appropriate, meta-analysis and network
(that is, indirect comparisons) meta-analysis will be conducted.
Discussion: Our systematic review will inform the decision of healthcare providers, policy-makers, Alzheimer’s patients
and family members about the use of cognitive enhancers, by improving their understanding of the costs, benefits and
harms that are associated with these agents.
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In 2010, approximately 35 million people world-wide
had Alzheimer’s dementia (AD). It has been projected
that by 2030, this figure will nearly double to 65.7 mil-
lion, and reach 115.4 million by 2050 [1]. In the United
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reproduction in any medium, provided the orbillion in 2010 and is estimated to soar to $1 trillion by
2050 [2]. AD is the most common cause of dementia [3].
It has an insidious onset with progressive deterioration
in cognition, functional ability, behavior, and mood [4].
Patients living with AD have a lower quality of life and AD
ultimately leads to death with a median survival of seven
years from diagnosis [5]. Currently, there is no cure for AD.
The management of AD focuses on slowing progression,
symptom control, maintaining functional status, improving
quality of life, minimizing adverse events, and decreasing
caregiver stress. Non-pharmacologic therapy includes socialtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ities of daily living, multidisciplinary programs [7], and pro-
viding support to caregivers [8]. The results of systematic
reviews examining these management strategies have found
marginal improvements in patient outcomes [6-8].
Recent cognitive enhancers for pharmacologic treatment
for AD include the cholinesterase inhibitor drug class
(donepezil, galantamine and rivastigmine), as well as mem-
antine, a N-methyl-D-aspartic acid (NMDA) receptor an-
tagonist [9]. The acetylcholinesterase inhibitors donepezil
(Aricept, Eisai/Pfizer) and rivastigmine (Exelon, Novartis)
have similar modes of action, increasing the concentration
of acetylcholine at the neurotransmitter sites[10]. Galanta-
mine (Reminyl, Shire) is another acetylcholinesterase in-
hibitor that increases acetylcholine at neurotransmitter
sites, yet also acts by modulating activity at nicotinic recep-
tors [10]. The NMDA receptor antagonist, memantine
(Ebixa, Lundbeck), works on the glutamatergic system and
modulates the neurotransmitter glutamate [10].
Although cognitive enhancers offer hope for patients
with AD, high dropout rates have been observed in ran-
domized trials of these agents and numerous adverse
drug reactions (ADRs), including nausea, vomiting, diar-
rhea, syncope and bradycardia, have been seen with their
use in practice [9]. None of these ADRs were identified
as being a major issue in the seminal randomized clinical
trials (RCTs) of efficacy [9]. Previously conducted sys-
tematic reviews of these agents have been limited by a
lack of comparisons across all available medications;
using restrictive inclusion criteria; and not selecting
studies for inclusion, abstracting data or evaluating study
quality in duplicate [11,12]. Furthermore, these system-
atic reviews did not examine adverse events from
sources other than RCTs (for example, cohort studies),
which would allow the identification of important ADRs.
Of critical importance, one study found that hospitalization
for bradycardia was associated with recent initiation of a
cholinesterase inhibitor and that more than half of the
patients who survived to discharge subsequently resumed
therapy, highlighting that clinicians underappreciated the
toxicity of this medication [13].
We are conducting this systematic review to determine
the comparative effectiveness, safety, and costs asso-
ciated with cognitive enhancers versus placebo, each
other, or best supportive care for AD and severe AD.
Furthermore, we wish to examine when each of the cog-
nitive enhancers should be stopped due to lack of
efficacy.Methods/design
This is a protocol for a systematic review, based on the
PRISMA Statement [14], which was registered with the
PROSPERO database (CRD42012001948).Eligibility criteria
We will include studies of elderly AD patients using cog-
nitive enhancers approved for use in Canada (donepezil,
rivastigmine, galantamine, memantine) compared with
other cognitive enhancers, memantine or placebo and/or
supportive care. Eligible studies include those with
patients with mild, moderate or severe AD. Mild AD is
defined as a score of 21 to 26 on the Mini-mental State
Examination (MMSE) [9], moderate AD as an MMSE
score of 10 to 20 and severe AD as an MMSE score <10.
The studies must report validated measures to diagnose
AD, including the Diagnostic and Statistical Manual of
Mental Disorders (DSM) criteria and the National Mini-
mum Data Set (NMDS) criteria. If the study includes
patients with mixed dementia, it will be included if the
predominant form of dementia is AD. Subgroups of inter-
est that we will explore through subgroup analysis include
severity of AD, previous response to treatment for AD,
presence of behavioral disturbance, comorbid conditions
(for example, stroke), and medication usage (for example,
statins; baseline, dosage, and pattern of cognitive enhan-
cers usage).
To be included in the analysis, the studies must report
at least one of the following outcomes: cognition, func-
tion, behavior, quality of life, costs or harms. To further
refine these outcomes, we engaged key stakeholders, in-
cluding patients and their caregivers, healthcare provi-
ders, and policy-makers. This is a form of ‘integrated
knowledge translation’ and we use a modified Delphi
process [15] to establish consensus across key stake-
holder groups. To facilitate the refinement of outcomes,
we will follow the three steps for considering the relative
importance of outcomes, as outlined by GRADE (Grad-
ing of Recommendations Assessment Development and
Evaluation) [16]: preliminary classification of outcomes
as critical, important but not critical or low importance
before reviewing the evidence; reassessment of the rela-
tive importance of the outcomes after reviewing the evi-
dence; and judgment of the balance between the
desirable and undesirable effects of an intervention. The
outcomes of interest (which will likely be rated differ-
ently by key stakeholder groups) include:
– Cognition: measured by any valid scale including the
MMSE, Alzheimer’s Disease Assessment Scale, Goal
Attainment Scale, Severe Impairment Battery
– Function: measured using any valid scale including
Alzheimer’s Disease Cooperative Studies Activities of
Daily Living Inventory, Alzheimer’s Disease
Functional Assessment and Change Scale, Bristol
Activities of Daily Living Scale, Caregiver-rated
Modified Crichton Scale, Disability Assessment for
Dementia, the Interview for Deterioration in Daily
Living Activities in Dementia, Nurses Observation
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subscale, the Progressive Deterioration Scale.
– Behavior: measured by any valid scale including the
Neuropsychiatric Inventory
– Global Status: measured by any valid scale including
Clinician Interview-Based Impression of Change
Incorporating Caregiver Information scale, Clinical
Global Impression of Change
– Clinical Outcomes: Mortality, Health-Related
Quality of Life, Institutionalization; harms (number
of adverse events (for example nausea, vomiting,
diarrhea, dizziness, weight loss, hospitalizations,
bradycardia), number of withdrawals, number of
withdrawals due to adverse events, severity and
timing of adverse events); benefits to caregivers (for
example caregiver stress).
– Costs and cost effectiveness
The primary outcomes are cognition and function as
measured by validated scales described above. Secondary
outcomes include behavior, global status, clinical out-
comes and costs.
We will include experimental studies (including RCTs,
quasi-randomized trials, controlled clinical trials) and
quasi-experimental studies (including interrupted time
series and controlled before and after studies). To look
for rare and unexpected adverse events and explore effi-
cacy and clinical monitoring over time, we will also in-
clude observational studies (for example, cohort, case
control studies). Inclusion will not be limited by publica-
tion status, time period or language of dissemination.
Articles not written in English will be translated to de-
termine their eligibility.
Information sources and literature search
Literature search strategies will be developed using med-
ical subject headings (MeSH) and text words related to
cognitive enhancers for AD. The databases searched will
include MEDLINE (OVID interface, 1946 onwards),
EMBASE (OVID interface, 1947 onwards), Cochrane Cen-
tral Register of Controlled Trials (CENTRAL; current
issue), CINAHL (EBSCO interface, 1981 onwards), and
Ageline (EBSCO interface, 1978 onwards).
The electronic database search will be supplemented by
searching for grey literature (that is, difficult to locate or
unpublished material). Specifically, we will search public
health and trial registry websites (for example, Public
Health Agency of Canada, Health Canada, FDA, metaReg-
ister of Controlled Trials), websites of organizations that
produce guidelines (for example, Canadian Agency for
Drugs and Technologies in Health, Center for Disease
Control and Prevention, World Health Organization,
Agency for Healthcare Research and Quality, National In-
stitute for Health and Clinical Excellence), conferenceabstracts (International Pharmaceutical conference), and
conduct general Internet searches in Google using key
phrases and terms. Relevant journals (Age and Aging and
the Journal of the American Geriatrics Society) will be
hand searched from 1990 to the present. We will contact
manufacturers to obtain their Scientific Information Pack-
ets for the medications. Reference lists of previous reviews
on a similar topic will be scanned to identify further mater-
ial [11,12]. Literature saturation will be ensured by search-
ing the authors’ personal files, contacting manufacturers of
cognitive enhancers, reviewing bibliographies from key
retrieved articles, forward citation searching using Scopus
and Web of Science, and contacting experts in the field,
such as clinicians, researchers, and the Drug Safety and Ef-
fectiveness Network for Observational Studies.
An experienced librarian (LP) will conduct the litera-
ture searches. The search strategy will be peer reviewed
by another librarian using Peer Review of Electronic
Search Strategies (PRESS) [17]. The draft literature
search can be found in Additional file 1. The results
from the literature search will be uploaded to our online
SysRev Tool [18]. This software will be used for screen-
ing the citations resulting from the search, as well as all
full-text articles identified through the search.
Study selection process
To ensure reliability, a training exercise will be con-
ducted prior to commencing screening. Using the inclu-
sion and exclusion criteria, a random sample of 50
citations from the literature search will be screened by
all reviewers. Inter-rater agreement for study inclusion
will be calculated using percent agreement and the
kappa statistic [19]. If poor to moderate agreement is
observed (that is, percent agreement less than 70% or a
kappa statistic less than 0.6), the inclusion and exclusion
criteria will be clarified to facilitate consistent applica-
tion of the selection criteria by the research team (for
example, we may need to clarify that AD does not in-
clude Lewy Body Dementia for the non-clinical reviewers
involved with this project). Reviewers will only abstract
data when the kappa statistic is greater than 0.6. Each cit-
ation will be screened by two independent reviewers using
the pre-specified inclusion and exclusion criteria. Poten-
tially relevant full-text articles will be obtained and screened
by two independent reviewers. Conflicts will be resolved by
discussion or the involvement of a third reviewer.
Data items and data collection process
The data abstracted will include study characteristics
(for example, study design, year of trial conduct, sample
size, setting, country of study conduct, intervention and
comparator details), participant characteristics (for example,
type and number of patients, age mean and standard devi-
ation, AD diagnosis criteria, AD severity, baseline cognition,
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tion, function, behavior, quality of life, costs, and harms).
The data will be extracted using the online SysRev Tool.
The online form will be piloted and will be further refined,
as necessary, if poor agreement is observed. Specifically, we
will review data abstraction elements contributing to the
low agreement and clarify the wording in the data collec-
tion forms to ensure that the data abstractors are interpret-
ing them in a similar fashion. To ensure data accuracy, two
reviewers will independently abstract all of the data and dis-
crepancies will be resolved by discussion or the involve-
ment of a third reviewer.
We suspect that in some instances studies will report
outcome results over many different time periods. We
will abstract data from each time period to examine the
effects of the interventions on the relevant outcomes
over time. Healthcare providers and policy-makers have
noted that the timepoints of greatest interest are at 6, 12
and 24 months in our discussions with them. Further-
more, many studies follow patients to three months and
we will also include this timepoint in our analysis.
We also suspect that multiple study publications may
report data from the same study group (that is, compan-
ion reports). When this occurs, the report with the crit-
ical outcomes of interest will be included and used to
abstract data. The other report(s) will provide supple-
mentary data only. We will contact the study authors for
further information when the data are not clearly
reported; this is particularly important for outcomes data
because outcomes that are positively influenced by treat-
ment are more likely to be reported [20].Methodological quality/risk of bias appraisal
We will appraise the methodological quality/risk of bias
using standardized quality assessment tools for design-
specific internal validity. For RCTs, we will use the
Cochrane Risk of Bias Tool [21]. For controlled clinical
trials, interrupted time series, and controlled before-after
studies, we will use the Cochrane Effective Practice and Or-
ganisation of Care Risk of Bias Tool [22]. For cohort studies
and case control studies, we will use the Newcastle-Ottawa
Scale [23]. Subsequently, we will use GRADE to create a
summary of findings tables and to assess the level of evi-
dence across studies. Publication bias will be assessed using
funnel plots [24].
Development of instruments for assessing risk of bias
in studies of harms is still in the early stages [25]. Santa-
guida and colleagues have developed a quality rating tool
for evaluating studies reporting harms based on a review
of the literature (called McHarm) [26]. It has been tested
for face and construct validity and we will use it in con-
junction with other standardized quality assessment
tools.Synthesis of included studies
The systematic review results will first be described nar-
ratively and, where possible, pooled estimates of effects
will be derived using a random-effects model [27]. Meta-
analysis will be performed separately for cognitive
enhancers versus placebo or best supportive care, against
each other, and versus memantine for severe AD. We
will not statistically combine the results of different
study designs in the meta-analysis. If the outcome is
continuous, then mean difference and its 95% confi-
dence intervals will be used. If the outcome is binary,
then the odds ratio will be used when observational
studies are assessed and the risk ratio will be used when
trials are analyzed.
When meta-analysis is conducted, we will assess for
clinical, statistical, and methodological heterogeneity.
We will look at the forest and funnel plots to assess for
obvious heterogeneity based on visual inspection. We
will also quantitatively assess heterogeneity; if extensive
heterogeneity is observed (for example, a statistically sig-
nificant chi-squared test (P< 0.1) for heterogeneity or an
I2 statistic greater than 60%) [28], we will conduct meta-
regression analysis. The meta-regression analysis will ex-
plore the influence of factors such as age, co-morbidities
(for example, chronic conditions), and baseline effect
sizes on the meta-analysis results. Meta-regression will
be done when ten or more studies are available [29].
Both meta-analysis and meta-regression will be analyzed
using SAS 9.2 [30].
We anticipate that some of the studies will not report all
relevant data and to include them in the analysis, we will
impute missing data using established methods [31]. We
will conduct sensitivity analysis to examine the effect of this
method using an approach proposed by Carpenter et al.
[32], which entails imputing missing data under a missing
at random assumption, and then reweights the imputed
data to allow for nonrandom selection.
If the data allow, network (that is, indirect compari-
son) meta-analysis will be conducted by using WinBUGS
(MRC Biostatistics Unit, Cambridge, England) to derive
the combined outcome between two treatments as well
as rank the efficacy among all available treatment arms
[33]. WinBUGS is a Bayesian software program used to
build complex statistical models using the Markov chain
Monte Carlo method. To facilitate the practicality of
treatment comparisons, median rankings will be used as
point estimations of treatment efficacy. A random effects
model with indirect/mixed treatment comparison based
on the WinBugs code derived by Ades et al. [33] will be
used for network meta-analysis. To distinguish between
significant and non-significant treatment efficacies, 95%
credible intervals (CIs) will be established using the 2.5
and 97.5 percentiles obtained via Monte Carlo simula-
tion of 10,000 iterations. We will interpret the 95% CI as
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frequentist methods [33]. We will base decisions about
combining studies on thorough investigations of clinical
and methodological diversity as well as variation in effect
size [Fu et al.]. We will do this by re-examining informa-
tion in the reports on some trials, calculating direct and
indirect estimates separately before proceeding to a net-
work meta-analysis [34].
To assess whether results are robust to trial design/
study quality, sensitivity analyses will be performed by
excluding trials with high rates of participant exclusions
where losses are considered to have the potential to im-
pact on the results. Sensitivity analysis will also be con-
ducted on imputing missing data (as described above),
instrument used for the primary outcomes example (we
will look at each of the validated instruments used for
assessing cognition separately if they are used in three
or more trials), average adherence between groups (we
will look at studies that reported the average adherence
and examine those that reported the lower adherence
rate and the higher adherence rate), and the impact of
including observational studies in the analyses (we will
combine trials and observational studies for this ana-
lysis only). Since network meta-analysis is based on the
Bayesian approach and is sensitive to the priors used in
the model, we will conduct sensitivity analysis using
different priors for variance parameters [35].
Discussion
Our systematic review results have the potential to in-
fluence a large proportion of the population. Of the
more than 0.5 million Canadians with dementia, 30% of
this group will have moderate dementia and two-thirds
of these will have AD indicating that more than
100,000 patients are eligible for cognitive enhancers.
However, in 2004 more than 900,000 prescriptions for
cognitive enhancers were filled and $129 million was
spent on these agents in Canada. The number of pre-
scriptions and money spent on cognitive enhancers is
only going to increase over time as the proportion of
people with AD continues to increase.
To ensure widespread dissemination of our results, we
will employ a multi-faceted knowledge translation strat-
egy. Firstly, we will publish our results in an open access
journal so that our results are widely available. Secondly,
we will present our findings at relevant meetings such as
those of the Cochrane Collaboration, Canadian Geriatrics
Society, American Geriatrics Society, and so on. Thirdly,
we will disseminate our results through newsletters of
interested organizations, such as the Drug Safety and Ef-
fectiveness Network in Canada, and the Alzheimer’s Soci-
ety among others. Fourthly, to facilitate changes in
knowledge, attitudes and behaviors of family physicians
we will link with continuing education providers to createan education module. In addition, we will use our results
to inform the development of a patient decision aid and
will create summary sheets of key results for clinicians
and healthy policy-makers, increasing the likelihood that
our results will be used. Lastly, we will disseminate find-
ings to social/mass media for mainstream uptake.
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